Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report.

@article{Arifi2012ActivityOI,
  title={Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report.},
  author={Samia Arifi and El Mehdi Tazi and Omar El mesbahi and Hassan Errihani},
  journal={Journal of gastrointestinal cancer},
  year={2012},
  volume={43 Suppl 1},
  pages={
          S145-7
        }
}
Anorectal melanomas (AM) are very rare tumors. They account less than 1% of all melanoma and less than 25% of mucosal melanomas [1]. They affect mostly older patients, and the majority of the patients are female. The prognosis of AM is extremely poor with 5-year survival of about 20% [1]. Unfortunately, conventional chemotherapy, immunotherapy, have failed to improve patients outcome. Recently approved antibody ipilimumab and the small molecule vemurafenib have shown to improve overall survival… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Similar Papers

Loading similar papers…